TIL
Instil Bio, Inc. (NASDAQ)
Healthcare — Biotechnology
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
None
1 analysts
$7.69
(0.00%)
Target:
$7.00
(-9.0%)
Sign in to add TIL to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $52.15M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.53 |
| EPS (TTM) | $-7.00 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -37.07% |
| Debt/Equity | 76.95 |
| Recommendation | None |
| Analyst Target | $7.00 |
| Analysts | 1 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 36.7 |
| Beta | 1.91 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $33.83 |
| 52-Week Low | $5.67 |
| 50-Day Avg | $7.96 |
| 200-Day Avg | $10.93 |
| Avg Volume | 25.5K |
| Volume | 44 |
Performance Analysis
NEUTRALTIL presents a mixed picture with both positive and negative indicators.
+
Trading near its 52-week low ($5.67), which could present a value opportunity.
~
RSI at 36.7 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none" from 1 analysts.
-
Average analyst target of $7.00 implies 9.0% downside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:34 UTC
Back to Screener Export Report